Biogen Pharma's Q3 financials show mixed results

Biogen Pharmachem Industries, a microcap trading company, recently announced its financial results for the quarter ended September 2023. The company reported a 75.61% growth in standalone net profit compared to the previous quarter, which saw a growth of 305.00%. However, the operating profit (PBDIT) excluding other income showed a decline of 110.00% in the same period, compared to a growth of 300.00% in the previous quarter.

The company's financial performance for the quarter has been deemed as flat, with a score of -1 compared to 0 in the last three months. Despite this, Biogen Pharma has shown some positive aspects in its financials. The half-yearly profit after tax (PAT) has increased to Rs 1.13 crore, surpassing the previous 12-month period's PAT of Rs 0.45 crore.

On the other hand, there are some areas of concern for Biogen Pharma. The quarterly profit before tax (PBT) excluding other income has fallen by 102.06% year on year, and the company's debtors turnover ratio for the half-yearly period is at its lowest in the last five periods. This indicates a slowdown in the company's pace of settling its debtors.

Despite the mixed financial results, MarketsMOJO has given a 'Sell' call for Biogen Pharma's stock. The company's financial performance for the quarter ended September 2023 has not met expectations, and it remains to be seen how the company will address the areas of concern in the upcoming quarters. Investors are advised to keep a close eye on Biogen Pharma's financial performance in the future.